The Wegovy 2.4 mg pen: what the trial evidence shows

What the clinical trials recorded at 2.4 mg

The clearest picture of what 2.4 mg can do comes from STEP 1, the phase 3 trial that formed the backbone of semaglutide's UK weight-management licence. Published in the New England Journal of Medicine, it followed 1,961 adults with obesity or overweight plus at least one weight-related condition for 68 weeks. Those assigned to semaglutide 2.4 mg lost an average of around 15% of body weight, compared with roughly 2.4% in the placebo group. A larger proportion (about one in three participants) lost more than 20%.

Those numbers describe a population average across a well-controlled trial. Individual results sit on a wide spectrum, shaped by starting weight, diet, activity, and how the body responds to semaglutide. Clinical trials are the most reliable guide to what is plausible; they are not a forecast for any single person. The NHS medicines page for semaglutide is a good starting point for understanding what to expect in practice.

It is also worth knowing that a higher dose, 7.2 mg, has since been approved by the MHRA for adults with a BMI of 30 or above. Trials reported around 20.7% average loss at that strength. Anyone curious about the full dose picture can read more about Wegovy's licensed dose range.

Why 2.4 mg is the endpoint, not the starting point

If you have come to this page after being told your next pen is 2.4 mg, the pace of the titration may have felt slow. That pace is deliberate. Semaglutide's titration schedule exists primarily to reduce gastrointestinal side effects (nausea, queasiness, loose stools) that are most common when the dose rises quickly. Starting at 0.25 mg and spending roughly a month at each rung before stepping up gives the body time to adjust.

The earlier pens (the 0.5 mg pen and the 1.0 mg pen) are doing a real job during this period, but the weight-management results seen in the trials were measured at Wegovy 2.4 mg, which is the strength where the licensed evidence is strongest. Reaching that level, and staying there consistently, is where the evidence base sits.

Your prescriber decides the timing of each increase. If side effects at a lower dose are still troublesome, pausing titration for a further four weeks is common. What matters most is finding a dose you can sustain, not one you reach quickly. The guide to Wegovy pen doses covers each step in more detail.

Side effects most commonly reported at this dose

Gastrointestinal effects are the most frequently reported: nausea, vomiting, diarrhoea, constipation, and indigestion. For most people these are most noticeable after each dose increase and settle within a week or two as the body adjusts. Fatigue, headache, and injection-site reactions are also listed in the summary of product characteristics.

There is something worth knowing about pancreatitis. Severe stomach pain that spreads to the back, with or without vomiting, is a signal to get medical help promptly, not to wait. The MHRA highlighted acute pancreatitis as an infrequent but serious risk in a January 2026 Drug Safety Update covering GLP-1 medicines broadly. This is not a reason to avoid treatment, but it is a reason to know the symptom. Gallbladder problems, including gallstones, have also been reported with semaglutide.

Anyone experiencing side effects, or simply unsure whether what they are feeling is expected, can contact the team through our support page. Unexpected or serious reactions should always be reported to a pharmacist, GP, or via the Yellow Card scheme.

Who the 2.4 mg pen is licensed for, and what that means in practice

The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not decide suitability. A prescriber looks at the full medical picture: current medications, medical history, and any conditions that might affect how semaglutide works or whether it is safe to use.

Wegovy is not recommended during pregnancy or breastfeeding, or for those actively trying to conceive. It is not licensed for anyone under 18. Women using oral contraceptives should be aware that guidelines recommend a non-oral method of contraception be added for four weeks after each dose increase, because GLP-1 treatment can slow stomach emptying and affect how oral medicines are absorbed. The NHS England weight-management injections guidance covers this, and discussing it with a prescriber before treatment starts is worthwhile.

For an overview of where Wegovy sits alongside other licensed options, our weight-loss treatment overview lays out the landscape clearly. And if cost is part of what you are thinking through, this page on Wegovy pricing in the UK gives honest context on what private treatment typically involves.